CPhI India 2015年世界制药原料印度展,将于2015年12月1-3日在印度孟买举行

  • 印度展,CPhI India,世界制药原料印度展,印度孟买

【展会简介】

第十届“世界制药原料印度展CPhI India 2015”将于2015年12月1-3日在印度孟买举行。它由UBM Live公司主办,是继CPhI Worldwide、CPhI Japan、CPhI China之后,在南亚市场新开辟的一大盛会。该展自 2005 年首届举办以来,凭借印度医药市场的蓬勃发展,吸引了来自全世界尤其是中国原料药生产商和贸易商的广泛关注。
2013年该展览会净面积约30000 平方米,共有来自中国、法国、德国、意大利、英国、美国、日本、新加坡等 86 个国家和地区的 800 多家公司参展,其中印度本土的参展公司近 350 家。展览会期间,到会的参观商达到 32000 人次,多数是来自印度、巴基斯坦、孟加拉国等南亚地区的生产商和贸易商。 CPhI India 2015 参展商
CPhI India 2015 商务旅游参展

【市场分析】

近年来,中印医药贸易保持了持续发展的良好态势。根据海关数据显示,截止至 2010 年底,进出口总额已由 2001 年的 3.93 亿美元增长至 2010 年的38.94 亿美元。中印医药保健品进出口额占中国医药贸易总额的比重为6.47%,印度已成为我国第四大医药贸易伙伴。在中印医药贸易中原料药占据了绝大部分份额,2010 年,中印原料药贸易额达 33 亿美元,占中国原料药进出口总额的比重达到 12.69%,印度成为中国第二大 API(原料药)贸易伙伴:中国向印度出口 29 亿美元,印度已超越美国成为中国原料药出口第一大国。

【参展产品】

大宗医药原料、乳化剂、溶化剂、药茶、中间体、油膏、磷脂、甜味剂、润滑剂、包衣剂、色素、化妆品原料、干扰素、诊断试剂、精细化工、胶质、药用植物、血清及疫苗、栓剂及片剂、活性配料、氨基酸、抗生素、抗菌防腐剂、酶、荷尔蒙及合成产品、胶囊、动植物提取物、保湿剂、抗氧化剂、催化剂等。

【展馆介绍】

孟买展览中心(BEC)是目前孟买最大、设施最完备的展览场馆,自1991年改建用于展览场馆后,迄今已经举办了数届的国际、国内展会。展馆位于Goregaon区西部高速公路旁,交通便利。从展馆到孟买国际、国内机场有10分钟的车程,离孟买北部新城城区20分钟车程。同时,展馆周边也有不少酒店,五星级酒店超过六家,车程15分钟左右。展馆周围也有相关的娱乐场所、商场等。

【展馆规模】

目前,BEC拥有1、2、5、6四个场馆,超过4万平方米。

5号馆展馆基本技术参数如下:

展馆面积:

A1室内7379平方米(171米x43米)

A2室外2978平方米(171米x17.40米)

展馆地面类型:

混凝土,承重10吨每平方米,适用于大型机械类展会。

馆高:最高15米

距离房梁管道12米

展馆净高6.75米摊位搭建限高6米

入口(宽×高):

G1,G2,G3:4.5米x4.5米

G4:4.9米x6米(适合大型机械出入)

G5:6米x6米(适合大型机械出入)

照明:钠化灯

电源电压:415/200伏特,50赫兹,3相。

卫生设施:1个。

其他设施:展馆空调、水、压缩空气、电话线、上网均可满足。

【展馆交通】


This link:http://www.chemcd.com/news/18959.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.